Intelligence · Clinical Development
Pipeline search results
Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Placebo to MK-6194, MK-6194
Merck Sharp and Dohme
Non segmental vitiligo
1 trial -
Placebo to Match GSK3915393 Tablet
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
1 trial -
Placebo to Match GSK3965193 Tablets
GlaxoSmithKline
Hepatitis B
1 trial -
Placebo to match ACP-204
Lacuna Pharma Pty Ltd
Alzheimer Disease psychosis
1 trial -
Placebo to match IMP Lu AG09222
H. Lundbeck A/S
Migraine
1 trial -
Placebo to match IMP TEV-56286, Emrusolmin
Lacuna Pharma Pty Ltd
Multiple System Atrophy
1 trial -
Placebo to match LY3540378
Eli Lilly Co.
Heart Failure with Preserved Ejection Fraction, Heart Failure
1 trial -
Placebo to match LY3556050
Eli Lilly Co.
Diabetic Peripheral Neuropathy
1 trial -
Placebo to match LY3848575
Eli Lilly Co.
Neuropathic Pain; Distal Sensory Polyneuropathy
1 trial -
Placebo transplantation
Chinese Academy of Sciences
Primary Ovarian Insufficiency
1 trial -
Placebo, APG777
Apogee Therapeutics
Atopic Dermatitis
1 trial -
Placebo, BFB759
Blue Earth Diagnostics Ireland Ltd
Hidradenitis Suppurativa
1 trial -
Placebo, GLUCOPHAGE 500 mg tabletki powlekane
Bial Portela & Companhia S.A.
idiopathic infertility
1 trial -
Placebos
BRIGHT MINDS BIOSCIENCES INC.
Cannabis
1 trial -
R7999 matching placebo, REGN7999
Lacuna Pharma Pty Ltd
Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Resultant Iron overload (IOL)
1 trial -
REGN7544, REGN7544 Matching Placebo
Lacuna Pharma Pty Ltd
Sepsis-Induced Hypotension
1 trial -
RO7204239, GYM329 Placebo
Hoffmann-La Roche
Facioscapulohumeral muscular dystrophy (FSHD)
1 trial -
RO7234292, RO7234292 Placebo
Hoffmann-La Roche
Prodromal and Early Manifest Huntington’s Disease
1 trial -
RO7790121 Placebo, RO7790121
Hoffmann-La Roche
Moderate to Severe Atopic Dermatitis (AD)
1 trial -
RO7790121 placebo, RO7790121
Hoffmann-La Roche
Moderate to Severe Rheumatoid Arthritis (RA)
1 trial -
RO7790121, RO7790121 placebo/diluent
Hoffmann-La Roche
Atopic Dermatitis
1 trial -
RTP-026 Placebo, RTP-026
Lacuna Pharma Pty Ltd
Patients with ST-Elevation Myocardial Infarction (STEMI)
1 trial -
Radotinib HCl, Placebo for Radotinib HCl
Alphapharm Pty Ltd
Treatment of Parkinson’s disease (PD)
1 trial -
Ramelteon and Placebo (25 possible combinations total)
Takeda
Chronic Insomnia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.